-Janssen Pharmaceutical - U.S. FDA Approves TECVAYLI, the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Press/Media

Period26 Oct 2022

Media coverage

2

Media coverage